• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Photodiagnosis and Photodynamic Therapy >Effect of vitamin A as a neoadjuvant agent in chemotherapy and photodynamic therapy of Rhabdomyosarcoma cells
【24h】

Effect of vitamin A as a neoadjuvant agent in chemotherapy and photodynamic therapy of Rhabdomyosarcoma cells

机译：维生素A作为横纹肌肉瘤化疗和光动力治疗中的新辅助剂的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Combinational therapy is among the most used treatment modality's to increase cancer treatment efficacy. It may also reduce side effects, treatment time, and development of drug resistance. The effects of different analogues of vitamin A (VA) as neoadjuvant agent were observed in this study with chemotherapeutic drugs (doxorubicin and methotrexate) and photodynamic therapy (PDT) using 5-ALA and Photogem as photosensitizers in RD cells. The uptake time of photosensitizer was optimized by means of spectrophotometric measurements. Diode laser (lambda = 635 nm +/- 1 nm) was used as an illumination source for PDT. Responses of administered drugs were assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. VA and its analogues exert prophylactic and therapeutic effects. Protective or antagonistic effects (CI 1) were observed in each of the case. These results propose that the use of VA as a neoadjuvant agent in combinational therapeutic modalities may reduce the efficacy of cancer treatment protocols as well as the existing side effects. Thus, VA is not the successful drug for combinational therapies and under treatment cancer patients should try to avoid its use with oxidative stress induction therapies (e.g. PDT, Radiotherapy, chemotherapy).
机译：组合疗法是最常用的治疗方式是增加癌症治疗效果。它还可能还减少副作用，治疗时间和耐药性的发展。在该研究中，在该研究中观察到不同类似物的维生素A（Va）作为Neoadjuvant代理的影响，所述药物药物（多柔比蛋白和甲氨蝶呤）和光动力治疗（PDT）使用5-Ala和Photogem作为RD细胞的光敏剂。光敏化器的摄取时间通过分光光度测量进行了优化。二极管激光（Lambda = 635nm +/- 1nm）用作PDT的照明源。通过3-（4,5-二甲基噻唑-2-基）-2,5-二苯基四唑溴铵（MTT）测定评估给药药物的反应。 VA及其类似物施加预防性和治疗效果。在每个情况下观察到保护或拮抗效应（CI> 1）。这些结果提出，在组合治疗方式中使用Va作为新辅助剂可降低癌症治疗方案以及现有副作用的疗效。因此，VA不是组合疗法的成功药物，并且在治疗癌症患者应尽量避免其与氧化应激感应疗法（例如PDT，放射治疗，化疗）一起使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号